Market Overview

Dougherty: Tornier Expected to Make Strong Progress, New Products Expected


According to a research report published today by Dougherty & Company, Tornier N.V.'s (NASDAQ: TRNX) fourth quarter extremity product sales growth was the strongest of the year.

In the report, Dougherty & Company commented, “TRNX reported fourth quarter revenue of $69.0 million compared to $61.3 million LY (forecast was $66.4 million), increases of 12.7% as reported and 12.4% in constant currency. Fourth quarter 2011 sales of Tornier's extremity product categories increased 17.5% as reported and 17.1% in constant currency and represented 79% of reported global sales.”

Dougherty & Company maintains its Buy rating and $33 PT on Tornier, which is currently trading at $24.47.

Posted-In: Dougherty & CompanyAnalyst Color Reiteration Analyst Ratings


Related Articles (TRNX)

Around the Web, We're Loving...

Get Benzinga's Newsletters

Our Experts vs. S&P 500Powered by Benzinga
Marketfy Products Return S&P 500
Morning Profit Maker 42.72% 6.69%
The Option Prophet 91.14% 6.69%
SecretCaps 26.55% 6.69%
Short-Term Trend Trading 11.89% 6.69%
View the highest rated products→